Treatment of chronic myelogenous leukemia with different cytokines.

abstract：:Skin findings can serve as a clue to internal disease. In this article, cutaneous manifestations of underlying lung malignancy are reviewed. Paraneoplastic dermatoses are rare, but when recognized early, can lead to early diagnosis of an underlying neoplasm. Malignancy-associated dermatoses comprise a broad group of h...

journal_title：Seminars in oncology

authors： Owen CE

更新日期：2016-06-01 00:00:00

abstract：:Gastrointestinal stromal tumor (GISTs) are the most common connective tissue malignancies of the gastrointestinal (GI) tract, with an incidence on the order of 10-13 per million people per year. Primary therapy is usually surgical, but the recurrence rate of large, so-called high-risk tumors, with a high mitotic rate,...

journal_title：Seminars in oncology

authors： Reichardt P,Hogendoorn PC,Tamborini E,Loda M,Gronchi A,Poveda A,Schöffski P

更新日期：2009-08-01 00:00:00

abstract：:Basket clinical trials are a new category of early clinical trials in which a treatment is evaluated in a population of patients with tumors of various histologic types and primary sites selected for containing specific genomic abnormalities. The objective of such studies is generally to discover histologic types in w...

journal_title：Seminars in oncology

authors： Simon R,Geyer S,Subramanian J,Roychowdhury S

更新日期：2016-02-01 00:00:00

abstract：:We report an update on a prospective observational trial for Waldenstrom's macroglobulinemia (WM) that called for re-registration to treatment with fludarabine (30 mg/m(2)) upon the development of symptomatic or progressive disease. Patients who did not require therapy for more than 1 year (n = 54) could be distinguis...

journal_title：Seminars in oncology

authors： Dhodapkar MV,Jacobson JL,Gertz MA,Crowley JJ,Barlogie B

更新日期：2003-04-01 00:00:00

abstract：:The current oncology practice of treating cancer with aggressive doses of radiation and chemotherapy is potentially disastrous, as response and side effects vary depending on several factors including pharmacogenetics. This study is the first to evaluate esophageal cancer treatment with a pharmacogenetic paradigm and ...

journal_title：Seminars in oncology

authors： Wu X,Lu C,Chiang SS,Ajani JA

更新日期：2005-12-01 00:00:00

abstract：:Lonidamine belongs to a new class of antineoplastics agents, since it does interfere with cell energy processes. When administered as single agent in metastatic breast cancer, it produces moderate therapeutic effects. The pattern of toxicity includes myalgias, asthenia, testicular pain, and gastrointestinal discomfort...

journal_title：Seminars in oncology

authors： Rosso R,Amoroso D,Gardin G,Miglietta L,Guido T,Pace M,Repetto L,Pronzato P

更新日期：1991-04-01 00:00:00

abstract：:Preclinical studies with zoledronic acid (Zometa; Novartis Pharmaceuticals Corp, East Hanover, NJ) have shown its potential in malignant bone disease. Clinical studies in the treatment of hypercalcemia of malignancy have been completed, as have phase I and II trials in patients with cancer and pre-existing bone metast...

journal_title：Seminars in oncology

authors： Coleman RE,Seaman JJ

更新日期：2001-04-01 00:00:00

abstract：:Data from various phase I/II studies of carboplatin in combination with paclitaxel (Taxol; Bristol-Myers Squibb Company, Princeton, NJ) have suggested that the degree of thrombocytopenia seen is less than that expected when carboplatin is given alone. However, some studies also have suggested that the area under the p...

journal_title：Seminars in oncology

authors： Calvert AH,Boddy A,Bailey NP,Siddiqui N,Humphreys A,Hughes A,Robson L,Gumbrell L,Thomas H,Chapman F

更新日期：1995-10-01 00:00:00

abstract：:Ifosfamide, an oxazaphosphorine analogue, is now commonly used in first-line anthracycline-containing regimens for advanced soft tissue sarcomas, based on its demonstrated single-agent activity in previously treated patients. At the Institut Gustave-Roussy, we performed a phase II study of high-dose ifosfamide without...

journal_title：Seminars in oncology

authors： Tursz T

更新日期：1996-06-01 00:00:00

abstract：:A substantial proportion of patients with squamous cell carcinoma of the head and neck have extensive locoregional disease at presentation. While extensive surgical procedures may completely eradicate local disease with acceptable morbidity for smaller tumors, in patients with stage III and IV disease, high local rela...

journal_title：Seminars in oncology

authors： Eisenberger M,Jacobs M

更新日期：1992-08-01 00:00:00

abstract：:A major consequence of administering increasingly aggressive therapies (chemotherapy with or without radiation therapy) in the treatment of non-small cell lung cancer is the adverse effects on the bone marrow that may lead to neutropenia, thrombocytopenia, and/or anemia. Myelosuppression or bone marrow toxicity may al...

journal_title：Seminars in oncology

authors： Ettinger DS

更新日期：2005-04-01 00:00:00

abstract：:Selective aromatase inhibitors cause regression of breast carcinomas by reducing estrogen production via inhibition of the enzyme aromatase (estrogen synthetase). A higher incidence of hormone-dependent breast cancer occurs in postmenopausal women than in younger women. Thus, total estrogen blockade is more likely to ...

journal_title：Seminars in oncology

authors： Brodie AM,Njar VC

更新日期：1996-08-01 00:00:00

abstract：:The management of metastatic prostate cancer that has relapsed after initial hormonal manipulation remains a major problem, with the majority of patients dying within 12 months. Their clinical course is frequently characterized by progressive debilitation, pain, and other tumor-related symptoms. A phase II, non-random...

journal_title：Seminars in oncology

authors： Raghavan D,Coorey G,Rosen M,Page J,Farebrother T

更新日期：1996-12-01 00:00:00

abstract：:The discovery that etoposide is one of the most active drugs in small-cell lung cancer (SCLC) led to its incorporation into a number of first-line combination chemotherapy regimens. The cyclophosphamide/doxorubicin/etoposide (CAE) regimen was shown to be as active or more active than other standard regimens in nonrand...

journal_title：Seminars in oncology

authors： Bunn PA Jr,Greco FA,Einhorn L

更新日期：1986-09-01 00:00:00

abstract：:High expression of the bcl-2 proto-oncogene is found in various human hematologic malignancies and solid tumors. Bcl-2 protein exerts its oncogenic role by preventing tumor cells from undergoing apoptosis induced by radiation, chemotherapy, and hormonal therapy. Antisense oligonucleotides directed toward the open read...

journal_title：Seminars in oncology

authors： Gutiérrez-Puente Y,Zapata-Benavides P,Tari AM,López-Berestein G

更新日期：2002-06-01 00:00:00

abstract：:Hematopoietic growth factors (HGFs) continue to be the most widely prescribed class of medications for patients with myelodysplastic syndromes (MDS), despite the advent of disease-modifying therapies for MDS (eg, azacitidine, decitabine, and lenalidomide) and the current absence of an MDS-specific US Food and Drug Adm...

journal_title：Seminars in oncology

authors： Steensma DP

更新日期：2011-10-01 00:00:00

abstract：:Hormonal therapy is very effective in the treatment of patients with metastatic breast cancer. Response to various therapies leads to improved quality of life and prolonged survival. This clinical trial compared two commonly utilized additive hormonal agents, tamoxifen citrate and megestrol acetate (Megace). Prelimina...

journal_title：Seminars in oncology

authors： Allegra JC,Bertino J,Bonomi P,Byrne P,Carpenter J,Catalano R,Creech R,Dana B,Durivage H,Einhorn L

更新日期：1985-12-01 00:00:00

abstract：:Capecitabine is an orally administered fluoropyrimidine carbamate that is preferentially converted to 5-fluorouracil in tumors relative to normal tissue. Three different dosing regimens were investigated in phase I studies: continuous monotherapy, intermittent monotherapy, and intermittent therapy supplemented with le...

journal_title：Seminars in oncology

authors： Seitz JF

更新日期：2001-02-01 00:00:00

abstract：:The majority of patients with advanced prostatic cancer respond either to castration or estrogen therapy. In an attempt to identify an alternative hormonal therapy, 25 symptomatic stage D prostate cancer patients were treated with megestrol acetate as initial hormonal therapy. Thirty-three patients were evaluable for ...

journal_title：Seminars in oncology

authors： Bonomi P,Pessis D,Bunting N,Block M,Anderson K,Wolter J,Rossof A,Slayton R,Harris J

更新日期：1985-03-01 00:00:00

abstract：:Paclitaxel (Taxol; Bristol-Myers Squibb Company, Princeton, NJ), the first taxane used in routine clinical practice, has aroused considerable interest for its high single-agent activity against breast cancer and for its novel mechanism of action. Epirubicin, the 4' epimer of doxorubicin, is another agent with a high a...

journal_title：Seminars in oncology

authors： Lück HJ,Thomssen C,du Bois A,Untch M,Lisboa B,Köhler G,Diergarten K

更新日期：1997-10-01 00:00:00

abstract：:In April 1990, the Argentine Group for Treatment of Acute Leukemia began a multicenter trial for the treatment of previously untreated acute myeloblastic leukemia patients who were under 21 years of age. Initial treatment consisted of an 8-day induction phase with cytarabine together with idarubicin on days 3 to 5 and...

journal_title：Seminars in oncology

authors： Sackmann-Muriel F,Fernández-Barbieri MA,Santarelli MT,Matus-Ridley M,Rosso A,Negri-Aranguren P,Cerutti I,Gomel M,Kvicala R

更新日期：1993-12-01 00:00:00

abstract：:Cisplatin has been employed in the treatment of non-small-cell lung cancer (NSCLC) since the late 1970s. Current evidence suggests that it may be the most effective single drug for the treatment of NSCLC patients. The overall response rate as a single agent is 21%, though responses are higher in previously untreated p...

journal_title：Seminars in oncology

authors： Bunn PA Jr

更新日期：1989-08-01 00:00:00

abstract：:The primary element involved in the practical delivery of hereditary cancer risk counseling is the development of a cancer genetics service. This service should involve a multidisciplinary core of specialists, aim to identify at-risk individuals and their families, and provide comprehensive genetic counseling with the...

journal_title：Seminars in oncology

authors： DeMarco TA,Smith KL,Nusbaum RH,Peshkin BN,Schwartz MD,Isaacs C

更新日期：2007-10-01 00:00:00

abstract：:Despite the high objective response rate of ovarian cancer to several reported platinum-based combination chemotherapy regimens, the majority of patients with advanced disease ultimately require consideration of a salvage regimen delivered for palliation of symptoms. A number of therapeutic strategies have been used i...

journal_title：Seminars in oncology

authors： Markman M

更新日期：1995-04-01 00:00:00

abstract：:Myeloid neoplasms are characterized by acquired somatic mutations and epigenetic alterations in genes that are crucial for hematopoietic differentiation and cellular proliferation and survival pathways. The heterogeneity and genetic complexity of these disorders is daunting, but the improvement in our knowledge of the...

journal_title：Seminars in oncology

authors： Odenike O,Thirman MJ,Artz AS,Godley LA,Larson RA,Stock W

更新日期：2011-04-01 00:00:00

abstract：:There are several treatment options for patients with metastatic colorectal cancer (mCRC), including those with disease that has progressed after treatment with chemotherapy. Bevacizumab-containing regimens show good efficacy in patients with previously treated disease. Compared with infused 5-fluorouracil, leucovorin...

journal_title：Seminars in oncology

authors： Giantonio BJ

更新日期：2006-10-01 00:00:00

abstract：:Colorectal cancer is the third most common cause of cancer-related death in both men and women. Surgery is the primary form of treatment, with greater than 90% of patients surviving 5 years or more. The remaining patients have metastatic disease, for which treatment options are limited. The fluoropyrimidine, 5-fluorou...

journal_title：Seminars in oncology

authors： Creemers GJ

更新日期：1997-12-01 00:00:00

abstract：:Because results with conventional salvage therapy remain disappointing, the approach of using high-dose therapy and bone marrow transplantation has gained increasing support in recent years. Several trials have now been reported using various conditioning regimens and hematopoietic rescue sources. Although it is not c...

journal_title：Seminars in oncology

authors： Vose JM,Bierman PJ,Armitage JO

更新日期：1990-12-01 00:00:00

abstract：:Cisplatin/etoposide/bleomycin (DEB) was given as an outpatient regimen in a novel weekly schedule to 27 patients with recurrent and/or widely metastatic cancer of the head and neck region. Six of these patients also received mitomycin (DEB/M) when their disease failed to respond after at least three weekly DEB doses. ...

journal_title：Seminars in oncology

authors： Osoba D,Band PR,Connors JM,Goldie JH,Knowling MA,Fetherstonhaugh EM

更新日期：1992-04-01 00:00:00

abstract：:Cancer cells that express excessive levels of Bcl-2 pose a major problem in the delivery of curative therapy. Most treatments for such cancer involve chemotherapy to induce the apoptotic process. While these therapies often result in disease control for periods of time, failure to initiate apoptosis as a result of acq...

journal_title：Seminars in oncology

authors： Cotter FE

更新日期：2004-12-01 00:00:00